Rocket Pharmaceuticals, Inc. (RCKT)
2.34
+0.10
(+4.46%)
USD |
NASDAQ |
Oct 20, 16:00
2.38
+0.04
(+1.71%)
After-Hours: 20:00
Rocket Pharmaceuticals Research and Development Expense (TTM) : 118.98M for June 30, 2026
Research and Development Expense (TTM) Chart
Historical Research and Development Expense (TTM) Data
| Date | Value |
|---|---|
| June 30, 2026 | 118.98M |
| March 31, 2026 | 131.80M |
| December 31, 2025 | 135.71M |
| September 30, 2025 | 143.55M |
| June 30, 2025 | 151.79M |
| March 31, 2025 | 155.54M |
| December 31, 2024 | 165.22M |
| September 30, 2024 | 169.80M |
| June 30, 2024 | 174.08M |
| March 31, 2024 | 179.49M |
| December 31, 2023 | 180.97M |
| September 30, 2023 | 189.49M |
| June 30, 2023 | 186.70M |
| March 31, 2023 | 176.80M |
| December 31, 2022 | 161.53M |
| September 30, 2022 | 141.53M |
| June 30, 2022 | 138.41M |
| March 31, 2022 | 122.22M |
| December 31, 2021 | 120.12M |
| September 30, 2021 | 141.55M |
| June 30, 2021 | 123.73M |
| March 31, 2021 | 116.24M |
| December 31, 2020 | 105.21M |
| September 30, 2020 | 69.36M |
| June 30, 2020 | 63.14M |
| Date | Value |
|---|---|
| March 31, 2020 | 60.52M |
| December 31, 2019 | 58.57M |
| September 30, 2019 | 67.67M |
| June 30, 2019 | 65.61M |
| March 31, 2019 | 62.39M |
| December 31, 2018 | 53.25M |
| September 30, 2018 | 34.50M |
| June 30, 2018 | 26.33M |
| March 31, 2018 | 18.37M |
| December 31, 2017 | 14.92M |
| September 30, 2017 | 19.49M |
| June 30, 2017 | 23.01M |
| March 31, 2017 | 26.66M |
| December 31, 2016 | 31.98M |
| September 30, 2016 | 28.41M |
| June 30, 2016 | 23.61M |
| March 31, 2016 | 19.10M |
| December 31, 2015 | 12.55M |
| September 30, 2015 | 7.572M |
| June 30, 2015 | 5.203M |
| March 31, 2015 | 5.111M |
| December 31, 2014 | 5.592M |
| September 30, 2014 | 6.247M |
| June 30, 2014 | 6.438M |
R&D Expense Definition
R&D expense is a line item from many companies' income statements.
Research and Development Expense (TTM) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Research and Development Expense (TTM) Benchmarks
| Sarepta Therapeutics, Inc. | 783.60M |
| Intellia Therapeutics, Inc. | 337.63M |
| Beam Therapeutics, Inc. | 408.66M |
| Arrowhead Pharmaceuticals, Inc. | 699.56M |
| Oncolytics Biotech, Inc. | 13.11M |